鼓励通用使用可以产生显著的节省。

Findings brief : health care financing & organization Pub Date : 2012-11-01

Christina Zimmerman

{"title":"鼓励通用使用可以产生显著的节省。","authors":"Christina Zimmerman","doi":"","DOIUrl":null,"url":null,"abstract":"Key findings. (1) Zero copayment for generic drugs is the greatest influencer of generic statin utilization. (2) Both higher copayments for generic drugs and lower copayments for competing brands are associated with a decreased probability of using generic statins. (3) Prior authorization and step therapy requirements for brand-name statins are associated with an increased use of generic drugs. (4) Greater use of generic statins should reduce costs for patients, plans, and Medicare.","PeriodicalId":83710,"journal":{"name":"Findings brief : health care financing & organization","volume":"15 8","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Encouraging generic use can yield significant savings.\",\"authors\":\"Christina Zimmerman\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Key findings. (1) Zero copayment for generic drugs is the greatest influencer of generic statin utilization. (2) Both higher copayments for generic drugs and lower copayments for competing brands are associated with a decreased probability of using generic statins. (3) Prior authorization and step therapy requirements for brand-name statins are associated with an increased use of generic drugs. (4) Greater use of generic statins should reduce costs for patients, plans, and Medicare.\",\"PeriodicalId\":83710,\"journal\":{\"name\":\"Findings brief : health care financing & organization\",\"volume\":\"15 8\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Findings brief : health care financing & organization\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Findings brief : health care financing & organization","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

关键的发现。(1)非专利药零共付是影响非专利他汀类药物使用的最大因素。(2)仿制药较高的共付额和竞争品牌较低的共付额都与使用仿制他汀类药物的可能性降低有关。(3)品牌他汀类药物的事先授权和分步治疗要求与仿制药使用的增加有关。(4)更多地使用非专利他汀类药物可以降低患者、计划和医疗保险的成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Encouraging generic use can yield significant savings.

Key findings. (1) Zero copayment for generic drugs is the greatest influencer of generic statin utilization. (2) Both higher copayments for generic drugs and lower copayments for competing brands are associated with a decreased probability of using generic statins. (3) Prior authorization and step therapy requirements for brand-name statins are associated with an increased use of generic drugs. (4) Greater use of generic statins should reduce costs for patients, plans, and Medicare.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Findings brief : health care financing & organization

自引率

0.00%

发文量